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Introduction
The annual American College of Cardiology congress was 
held in New Orleans from 16 to 18 March 2019, during 
which the results of numerous clinical studies that could 
have a significant impact on the everyday practice of car-
diologists were presented. Much attention was devoted to 
new technologies that are changing the philosophy behind 
medical research — used e.g. in the Apple Heart Study. 
Several promising new drugs have not lived up to expecta-
tions — e.g. neladenoson in heart failure with preserved 
ejection fraction, while some effective therapies [e.g. 
TYRXTM antibacterial pocket reducing the risk of infection 
with the cardiac stimulator bed in the WRAP-IT (World-wide 
Randomised Antibiotic Envelope Infection Prevention Trial) 
study] have no chance of routine use due to their low cost-
effectiveness. However, in the authors’ opinion, several of 
the presented studies were of great importance for cardio-
logical practice, indeed sometimes even groundbreaking 
importance. Below we present our subjective selection.
Transcatheter aortic valve implantation  
in patients with severe aortic stenosis  
and low operational risk — PARTNER 3  
and EVOLUT studies
Transcatheter aortic valve implantation (TAVI) is an alterna-
tive to surgery in patients with severe aortic stenosis. Until 
recently, this was reserved for patients at high risk of dying 
from conventional surgery. This year’s congress brought 
groundbreaking data on the clinical results of TAVI used in 
low-risk patients. In the PARTNER 3 [1] and EVOLUT Low 
Risk [2] studies, TAVI results were compared to those of 
surgical aortic valve replacement (SAVR) in patients with 
severe aortic stenosis and low risk of death during surgery 
in very similar patient populations [mean age approxima-
tely 74 years, calculated risk of death STS-PROM (Short 
Term Risk Calculator — Predicted Risk of Mortality) 1.9%]. 
1,000 patients were enrolled in the PARTNER 3 trial and 
randomly assigned to TAVI (balloon-expanded SAPIEN 3 
valve) or SAVR. The primary endpoint in the study was de-
ath from any cause, stroke or rehospitalisation within one 
year of surgery. The results of the study were surprising — 
contrary to current guidelines, significant clinical benefits 
were demonstrated in the group treated with transcatheter 
surgery. Within one year, the primary endpoint occurred in 
8.5% of the TAVR group compared to 15.1% SAVR — a highly 
significant indicator of the advantage of a TAVI strategy (risk 
reduction by an impressive 46%, p = 0.001). Analysis of 
the annual occurrence of the primary endpoints showed 
a clear advantage of the transcatheter strategy: mortality 
1.0% versus 2.5% (TAVI versus SAVR), stroke rate 1.2% ver-
sus 3.1% (a 62% decrease in risk), and 35% less frequent 
rehospitalisations — 7.3% vs. 11%. Two patients from the 
TAVI group and four from the surgical group died during 
hospitalisation. The hospital stay was significantly reduced, 
from seven to three days, thanks to TAVI. Patients treated 
with the transcatheter method required implantation of 
a cardiostimulator with a frequency similar to SAVR [6.5% 
vs. 4%, p = NS (not statistically significant)], while much 
less frequently (5% vs. 39.5%) developed atrial fibrillation 
in the month after the procedure. There were no clinical 
manifestations of valve thrombosis in any of the groups, 
and the percentage of moderate or large return waves on 
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somewhat less challenging thanks to the results of the 
randomised AUGUSTUS study [3].
This study included 4,614 patients from centres in 
North America, Europe, Asia and South America, in whom 
AF was an indication for chronic oral anticoagulation, and 
in whom acute coronary syndrome (ACS) was diagnosed 
or percutaneous coronary intervention (PCI) was perfor-
med. Over 92% of patients were treated with clopidogrel 
(and the others with other P2Y12 inhibitors). Two equally 
numerous patient groups were randomly assigned in 
a 2 × 2 schedule to two alternative therapies: apixaban 
(fixed-dose for AF) or vitamin K antagonist (VKA), plus 
in addition acetylsalicylic acid (ASA) at 81 mg/day or 
a placebo. The primary endpoint was major bleeding or 
other clinically significant bleeding during the six months 
of follow-up. Secondary endpoints included death or ho-
spitalisation due to stroke, myocardial infarction, stent 
thrombosis or urgent revascularisation. The results of 
the study were in line with previous observations on new 
anticoagulants (RE-DUAL studies with dabigatran and 
PIONEER-AF with rivaroxaban), indicating the superiority 
of apixaban over VKA and the possibility of limiting indi-
cations to ASA. After six months of treatment, the risk 
of bleeding was reduced by 31% among patients taking 
apixaban compared to warfarin (p < 0.001) and by 47% 
among patients taking a placebo compared to aspirin. 
The highest bleeding rates were observed among patients 
treated with VKA with dual antiplatelet therapy (18.7%), 
and the lowest among those taking clopidogrel, apixaban 
and placebo (7.3%). The primary endpoint (major bleeding 
or clinically significant bleeding) occurred in 10.5% of pa-
tients receiving apixaban compared to 14.7% of patients 
receiving AWK (p < 0.001). The rate was 16.1% in the ASA 
randomisation analysis and 9% in the case of the placebo. 
The number of deaths and hospitalisations (the study’s 
secondary endpoint) was highest in patients receiving 
AWK and ASA (27.5%), and lowest in patients receiving 
apixaban and placebo (22.0%). Apixaban reduced the risk 
of a secondary endpoint relative to AWK by 17%, while 
ASA did not change the risk relative to placebo. A 50% 
lower risk of stroke was observed in patients in the api-
xaban group compared to patients taking VKA. Patients 
enrolled to the study after acute coronary syndrome had 
a significantly reduced risk of bleeding during treatment 
with apixaban compared to VKA and when taking placebo 
versus ASA.
AUGUSTUS confirms that the treatment of patients 
with AF requiring antiplatelet therapy with new anticoa-
gulants is safe, and the combination of apixaban and 
clopidogrel, without ASA, can be a safe treatment regimen 
in this difficult patient population, without a significant 
increase in the risk of ischaemic events such as heart 
attack or stroke.
the new valve was similar (0.6% and 0.5% after a year). 
Mild reverse waves, as well as subclinical (asymptomatic) 
thrombosis were less common after SAVR.
The EVOLUT Low-Risk study included 1,468 patients 
with random assignment to TAVI (CoreValve, Evolut R, 
Evolut PRO, Medtronic self-expanding valves) or SAVR. The 
primary endpoint of the study was the incidence of the 
primary endpoint (death or stroke resulting in disability) in 
the 24-month follow-up. This was 5.3% in the TAVI group 
compared to 6.7% SAVR — therefore TAVI was non-inferior 
to cardiac surgery. TAVI proved to be a safer method — the 
secondary endpoint concerned peri-operative complica-
tions over a 30-month period, occurring in 5.3% of patients 
in the TAVI group, and in 10.7% after cardiac surgery. After 
30 days, patients after TAVI had lower incidences of stroke 
causing disability (0.5% vs. 1.7% after SAVR), haemorrhagic 
complications (2.4% vs. 7.5% after SAVR), acute kidney 
damage (0.9 % vs. 2.8% after SAVR), and atrial fibrillation 
(7.7% vs. 35.4% after SAVR). At the same time, patients 
after TAVI reported a higher quality of life after 30 days. 
After a year, 2.4% of patients after TAVI and 3% after SAVR 
(p = NS) died. Due to the different design of the TAVI valves, 
unlike in the PARTNER study, patients treated with the 
transcatheter method required more frequent cardiac pace-
maker implantation (19.4% vs. 6.7% after SAVR), but atrial 
fibrillation was also observed much less frequently (9.8% 
vs. 38.3%) and there were fewer hospitalisations for heart 
failure (3.2% vs. 6.5%, annual follow-up). Valve thrombosis 
in both groups was very rare (< 1%). The frequency of mo-
derate or large return waves on the new valve was slightly 
higher after TAVI (3.5% vs. 0.5% after a year), but moderate 
or significant valve mismatch (too low effective outlet area) 
was less common after transcatheter treatment (1.78% vs. 
8, 2% after SAVR). Therefore, the study showed at least the 
clinical equivalence of TAVI using a self-expanding valve 
compared to SAVR.
Both studies analysed for the first-time groups of pa-
tients with severe arterial stenosis and low operational 
risk, who comprise 80% of those currently undergoing 
surgery. Considering the data from the EVOLUT and 
PARTNER 3 studies, it seems justified to treat TAVI as an 
acceptable and perhaps more appropriate  therapeutic 
alternative also for low-risk patients. However, planned 
future research still needs to assess the long-term effects 
of both strategies.
AUGUSTUS study supports the use  
of apixaban as part of DAPT  
for most patients with AF after ACS or PCI
The dilemma of risk and benefits dependent on anticoa-
gulation in patients with atrial fibrillation (AF) and the 
indication for dual antiplatelet therapy may have become 
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Home treatment for low-risk pulmonary 
embolism with rivaroxaban — the Home 
Treatment of Pulmonary Embolism  
(HoT-PE) trial
One of the most important studies for clinical practice 
discussed at the ACC’s 2019 congress was one with the 
acronym HoT-PE (Home Treatment of Pulmonary Embolism 
Trial) aimed at assessing whether the early termination of 
hospitalisation (i.e. within 48 hours of admission) followed 
by community-based treatment with rivaroxaban of patients 
with a low-risk acute pulmonary embolism (APE) is effective 
and safe [4]. Patients were qualified to the low-risk group 
using the Hestia criteria, which have many overlapping fea-
tures with the PESI scale but do not exclude patients older 
than 80 years or those with cancer. Rivaroxaban 2 × 15 mg/ 
/day was initiated in the hospital and continued for three 
weeks after discharge, followed by rivaroxaban 1 × 20 mg 
or 15 mg in selected patients for at least three months. The 
average hospitalisation time in the study was 34 hours, with 
93.6% of patients discharged within 48 hours. Recurrence 
of symptomatic venous thromboembolism (VTE) or fatal 
APE (endpoint of efficacy) within three months occurred in 
3/525 patients (0.6% — only PE recurrences, no deaths). 
The efficacy rate was one-third of the 1.7% threshold set 
by researchers based on 3-month VTE recurrence rates 
in previous home-based and EINSTEIN PE studies. In this 
study, there were two deaths due to advanced cancer. In 
the HoT-PE study, a single dose of heparin was administered 
to only 10% of patients (rivaroxaban was preferred from 
the beginning of treatment). Aspects of safety assessed 
separately were favourable — major bleeding (six out of 
519 patients), any clinically significant bleeding (31 out of 
519) or at least one serious adverse event (58 out of 519) 
rarely occurred. Only 2.3% of patients were re-hospitalised 
for suspected APE recurrence or bleeding.
Therefore, it appears that in patients with low-risk acute 
pulmonary embolism, without right ventricular dysfunction 
and intracardiac thrombi, early discharge and rivaroxaban 
treatment at home is effective and safe.
The results of the HoT-PE study strengthen the legi-
timacy of PE patients for outpatient treatment with oral 
anticoagulants, possibly reducing hospital complications 
and healthcare costs.
Alcohol abstinence and the occurrence  
of atrial fibrillation
One of the more important preventive studies was a ran-
domised study on the effects of abstinence in people who 
drink moderate amounts of alcohol and have AF [5]. The 
study included 140 patients with paroxysmal (63%) or 
persistent AF (37%), currently in sinus rhythm, who consu-
med at least 10 alcohol equivalents weekly (12 g ethanol). 
Rhythm monitoring was carried out using an implantable 
loop recorder or pacemaker or an AliveCor home single-
-channel recorder. In the study group, all patients consented 
to total abstinence, which was checked by urine analysis 
for the alcohol metabolite. In the control group, drinking 
alcohol was allowed. Among patients with moderate alcohol 
consumption, alcohol abstinence was independently asso-
ciated with a reduction in the duration of AF (5.6% ± 12.4% 
compared to 8.2% ± 14.5%), a reduction in the frequency 
of AF relapse, an improvement in arrhythmia symptoms, 
weight loss, and improved blood pressure control. The 
results of this study indicate that the recommendation of 
alcohol abstinence should be part of lifestyle interventions 
in people with AF who drink moderate amounts of alcohol.
Dapagliflozin in heart failure with reduced 
ejection fraction — DECLARE TIMI-58 study
The results of the large-scale DECLARE-TIMI 58 (Dapagli-
flozin and Effects on Cardiovascular Events) study suba-
nalysis regarding the effects of treatment in patients with 
heart failure were eagerly awaited [6].
17,160 patients with type 2 diabetes mellitus and con-
comitant cardiovascular disease (41%) or its high risk (59% 
of the group) participated in the DECLARE-TIMI 58 study. 
Randomisation required adding 10 mg of dapagliflozin or 
placebo to regular diabetes medication (diabetes having 
lasted approximately 10 years on average). The median 
follow-up was four years. The current results use the fact 
that at the beginning of the study 30% of participants 
(5,202) had their left ventricular ejection fraction assessed, 
thus 13% of patients (671) were diagnosed with heart fai-
lure with reduced ejection fraction (HFrEF). It was observed 
that in this subgroup dapagliflozin reduced mortality due 
to cardiovascular diseases or the risk of hospitalisation 
due to heart failure to a greater extent (by 38%) than in 
other patients (by 12%, NS; p for interaction = 0.046). Most 
importantly, dapagliflozin reduced cardiovascular mortality 
by 45% and total mortality by 41% in patients with HFrEF, 
but not in people without HFrEF (HR 1.08, p = NS). The 
effect of the drug on mortality due to circulatory reasons 
and overall mortality showed a clear interaction with the 
decreasing left ventricular ejection fraction, disappearing 
above EF = 45%. Treatment also reduced the incidence of 
HF hospitalisation in both HFrEF (by 36%) and not-HFrEF 
(by 24%) patients.
Left ventricular ejection fraction (as well as a history 
of heart failure) is, therefore, an important parameter for 
identifying people with type 2 diabetes who may benefit 
particularly from SGLT2 inhibitors.
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Antidote reversing the effect of ticagrelor  
— the molecule PB2452
Antiplatelet therapy is an important part of secondary 
prevention of cardiovascular events, but the possibility of 
reversing the effects of new oral anticoagulants is a major 
problem in everyday practice. The congress presented 
the first clinical evaluation of the PB2452 molecule as 
a method of reversing ticagrelor’s effect [6].
Platelet function was tested in 64 healthy volun-
teers before treatment with ticagrelor and then after 
PB2452 (48 people) or placebo (16 people). Platelet 
aggregation was shown to be inhibited by approximately 
80% after 48 hours of ticagrelor treatment. The new drug 
PB2452 was given as an initial intravenous bolus followed 
by a prolonged infusion (eight, 12 or 16 hours) and reversed 
the antiplatelet effect of ticagrelor within five minutes of 
treatment onset. This effect lasted for over 20 hours. No 
evidence of increased platelet activity (rebound effect) was 
observed after drug discontinuation, and drug-related ad-
verse events were mainly related to infusion site problems. 
Study results indicate that intravenous administration of 
PB2452 can provide immediate and permanent reversal 
of ticagrelor’s antiplatelet effect, which would be a unique 
opportunity for patients who need urgent surgery or expe-
rience life-threatening bleeding during ticagrelor therapy.
Does bempedia acid decrease  
LDL concentration — CLEAR Wisdom study
Another eagerly awaited study in the field of preventive 
cardiology was the CLEAR Wisdom study assessing the 
clinical possibilities of a new drug — bempedia acid [8]. This 
is a new drug that works in the same way as statins on the 
cholesterol synthesis pathway in the hepatocyte, but at an 
earlier stage — by inhibiting ATP-citrate lyase. Importantly, 
the safety profile of activated bempedia acid is not present 
in skeletal muscle. In the CLEAR Wisdom study, 779 pa-
tients were randomly assigned to treatment with 180 mg 
bempedic acid or placebo (for one year, in addition to the 
maximum tolerated statin doses) to assess the long-term 
efficacy and safety of patients at high risk for cardiovascular 
disease. A subgroup of 77 patients did not tolerate any 
statin dose. 740 patients (490 bempedia acid, 250 pla-
cebo) completed the study. Low-density lipoprotein (LDL) 
cholesterol in the bempedia acid group decreased from 
119.4 mg/dL to 97.6 mg/dL at week 12 compared to no 
change from baseline in the placebo group (122.4 mg/dL 
vs. 122.8 mg/dL). The mean percentage change in plasma 
LDL cholesterol was 15.1% for bempedia acid compared 
to 2.4% for placebo (p < 0.001). In patients not using sta-
tins, the decrease in LDL cholesterol was about 25%. The 
addition of bempedia acid to the maximally tolerated statin 
dose in patients with hypercholesterolemia significantly and 
permanently reduced total cholesterol, LDL cholesterol, 
non-high-density lipoprotein (HDL) cholesterol, apolipo-
protein B, and C-reactive protein compared to placebo. 
Side effects were similar to placebo, without any excessive 
muscle discomfort.
The CLEAR Wisdom study indicates that bempedia acid 
may extend the range of treatment options for high-risk 
patients with atherosclerotic cardiovascular disease whose 
LDL cholesterol levels remain unsatisfactory due to statin 
intolerance — drug tolerance appears to be better.
Apple Watch helps detect AF  
— is this the future?
Today’s patients have more options than ever before to mo-
nitor their own health data, and make decisions about what 
to do with such information, in the era of smartwatches 
and other devices, as well as new applications designed 
to monitor heart rate and other parameters.
The Apple Heart Study was designed to assess whether 
the Apple Watch can reliably detect AF and encourage 
subsequent clinical evaluation [9]. In the first study of this 
kind, which involved 419,927 (!) people, using an Apple 
Watch to identify an irregular rhythm was found to help 
identify AF. The results showed that 2,161 participants 
(0.5% registered) received an irregular rhythm notifica-
tion. Of the 200,000 participants under the age of 40, 
the notification rate was 0.16% compared to 3.2% in the 
25,000 people aged 65 or older. A positive predictive value 
of 84% confirms the ability to correctly identify AF among 
people who have been informed of an irregular rhythm by 
their Apple Watch. This study confirmed the soundness of 
the concept of using non-medical portable devices for me-
dical applications, and will probably have a more clinically 
oriented continuation (HEARTLINE study).
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